Dear Colleagues,
I am thrilled to announce that the SCI has been successfully re-designated as a Comprehensive Cancer Center by the National Cancer Institute, one of only 51 such centers in the country. This is the SCI’s first renewal as a NCI-designated Comprehensive Cancer Center since first receiving the comprehensive designation in 2015. Our designation is the result of the competitive Cancer Center Support Grant (CCSG) funding mechanism through the NCI’s Cancer Centers Program. The SCI will receive a five-year, $21 million grant renewal for the funding period 2022 – 2027, a 20% increase in the funding provided to the SCI by the NCI.
The NCI Cancer Centers Program was created as part of the National Cancer Act of 1971 and is one of the anchors of the nation’s cancer research effort. Through this program, NCI recognizes centers around the country that meet rigorous standards for transdisciplinary, state-of-the-art research focused on developing new and better approaches to preventing, diagnosing, and treating cancer. Our success in being re-designated by the NCI is a reflection of our outstanding cancer science, translation, clinical research and clinical care. It’s a shared accomplishment and a team effort by our superb faculty, trainees, nurses and staff. I would like to once again express my deep gratitude to everyone involved in the complex and lengthy renewal process.
Sincerely,
Steve
STEVEN ARTANDI, MD, PhD
Laurie Kraus Lacob Director, Stanford Cancer Institute
Jerome and Daisy Low Gilbert Professor of Medicine and Biochemistry
–––––––––––––––––––––––––––––––––––––––––––––––––
265 Campus Dr, G2167 | Stanford, CA, 94305
t. 650.736.0975
Search available clinical trials
Follow me on Twitter at @SCIDirector
